Yihong Y Yao

US Patent:

20100143372, Jun 10, 2010

Filed:

Dec 6, 2007

Appl. No.:

12/517333

Inventors:

Yihong Yao - Boyds MD, US
Bahija Jallal - Potomac MD, US
Ricardo Cibotti - Bethesda MD, US
Anthony Coyle - Washington DC, US
Peter Kiener - Potomac MD, US

Assignee:

MEDIMMUNE, LLC - Gaithersburg MD

International Classification:

A61K 39/395
C12Q 1/68

US Classification:

4241581, 435 6

Abstract:

The present invention encompasses type-1 IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFNα activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognosis to patients having IFNα-induced disorders.

US Patent:

20100261172, Oct 14, 2010

Filed:

May 5, 2008

Appl. No.:

12/598526

Inventors:

Yihong Yao - Boyds MD, US
Bahija Jallal - Potomac MD, US
Ricardo Cibotti - Bethesda MD, US
Anthony Coyle - Washington DC, US
Peter Kiener - Potomac MD, US

Assignee:

MEDIMMUNE, LLC - Gaithersburg MD

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFNα activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognosis to patients having IFNα-induced disorders.

US Patent:

20110243929, Oct 6, 2011

Filed:

Dec 17, 2010

Appl. No.:

12/971469

Inventors:

Anthony COYLE - Boston MA, US
Yihong Yao - Boyds MD, US
Bahija Jallal - Potomac MD, US
Gianluca Carlesso - Rockville MD, US
Michael Bowen - Rockville MD, US

Assignee:

Medlmmune, LLC - Gaithersburg MD

International Classification:

A61K 39/395
C07K 16/18
C07H 21/04
C12N 15/63
C12N 5/10
A61P 37/06

US Classification:

4241331, 5303873, 536 2353, 4353201, 435325

Abstract:

The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonisation) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.

US Patent:

20110256155, Oct 20, 2011

Filed:

Apr 18, 2011

Appl. No.:

13/088751

Inventors:

Jiaqi Huang - Potomac MD, US
Haifeng Bao - Rockville MD, US
Philip Brohawn - Jefferson MD, US
Patricia Burke - Ranson WV, US
Xiaoru Chen - Sterling VA, US
Theresa Lavallee - Rockville MD, US
Yihong Yao - Boyds MD, US

Assignee:

MEDIMMUNE, LLC - Gaithersburg MD

International Classification:

A61K 39/395
A61P 35/00
C12Q 1/68

US Classification:

4241741, 435 61, 435 614, 435 612

Abstract:

The invention relates to a rapid, sensitive method to obtain a gene expression profile from a target cell population in a blood sample. The target cells can be circulating tumor cells. Disclosed are methods and kits for obtaining such profiles.

US Patent:

20110262928, Oct 27, 2011

Filed:

Feb 6, 2009

Appl. No.:

12/866586

Inventors:

Yihong Yao - Boyds MD, US
Chris Moorehouse - Middletown MD, US
Brandon Higgs - Gaithersburg MD, US
Bahija Jallal - Potomac MD, US
Steven A. Greenberg - Newton MA, US

Assignee:

Medimmune LLC - Gairthersburg MD

International Classification:

C12Q 1/68

US Classification:

435 617, 435 618, 435 61

Abstract:

The present invention encompasses miRNA profiles and type-I IFN/IFNα-induced PD marker profiles in inflammatory or autoimmune disorders, such as myositis. The profiles may also be used in, for example, methods of treating patients, methods of monitoring disease progression of patients, and in diagnosing or providing a prognosis to patients having inflammatory or autoimmune disorders.

US Patent:

20110287022, Nov 24, 2011

Filed:

Jun 19, 2009

Appl. No.:

12/999626

Inventors:

Yihong Yao - Boyds MD, US
Bahija Jallal - Potomac MD, US
Ricardo Cibotti - Bethesda MD, US
Anthony Coyle - Boston MA, US
Peter Kiener - Potomac MD, US
Barbara White - Finksburg MD, US

Assignee:

Medlmmune, LLC - Gaithersburg MD

International Classification:

A61K 39/395
C40B 30/04
A61P 29/00
A61P 17/06
A61P 19/02
G01N 33/53
C12Q 1/02

US Classification:

4241581, 436501, 506 9, 435 29

Abstract:

The present invention encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFNα activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognoses to patients having IFNα-induced disorders.

US Patent:

20120251546, Oct 4, 2012

Filed:

Sep 2, 2010

Appl. No.:

13/393616

Inventors:

Brandon Higgs - Gaithersburg MD, US
Wei Zhu - Boyds MD, US
Chris Morehouse - Middletown MD, US
Barbara White - Finksburg MD, US
Bahija Jallal - Potomac MD, US
Yihong Yao - Boyds MD, US

Assignee:

MEDIMMUNE LLC - GAITHERBURG MD

International Classification:

A61K 39/395
G06F 19/00
G01N 21/64

US Classification:

4241421, 435 611, 4241581, 4241721, 702 19

Abstract:

The present disclosure encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that modulates type 1 interferon activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognosis to patients having IFNα-induced disorders.

US Patent:

20120283121, Nov 8, 2012

Filed:

Oct 11, 2010

Appl. No.:

13/501542

Inventors:

Jiaqi Huang - Potomac MD, US
Chris Morehouse - Middletown MD, US
Katie Streicher - Bethesda MD, US
Brandon W. Higgs - Gaithersburg MD, US
Yihong Yao - Boyds MD, US
Theresa Lavalle - Rockville MD, US

Assignee:

MEDIMMUNE, LLC - Gaithersburg MD

International Classification:

C12Q 1/68
C40B 30/04
C07H 21/04

US Classification:

506 9, 536 2431, 435 612, 435 611

Abstract:

Without limitation, this disclosure relates to compositions and methods for detecting and quantifying the expression of insulin receptor isoform A (IR-A) and/or insulin receptor isoform B (IR-B) in a tissue sample. The disclosure also relates to methods of diagnosis and classification based at least in part upon detecting and quantifying the expression of insulin receptor isoform A (IR-A) and/or insulin B (IR-B) in a tissue sample. Methods of treating a subject based upon such a classification are among additional aspects of the disclosure presented herein.